News

AST SpaceMobile, Inc. ASTS shares were up 18.3% yesterday, driven by the euphoria related to its upcoming BlueBird satellite launch on Dec. 15. The uptrend was also buoyed by OpenAI CEO Sam Altman’s

The market’s rally has been fueled by AI for quite some time now, with the “Magnificent Seven” significantly outperforming the S&P 500 and accounting for much of the gains. This outperformance is

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 85.43% from its 52-week low price of $66.66/share.

But

KBR, Inc. KBR has expanded its U.K. presence after securing a U.S. Navy contract to provide Foreign Military Sales support for the Naval Air Systems Command’s (NAVAIR) F/A-18 and EA-18G Program

Amicus Therapeutics FOLD has been making meaningful progress with its lead product, Galafold (migalastat), which has been driving the majority of the company’s revenues. The drug has remained a key

Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock gained 5.84% following the announcement.

The deal centers on future net sales

Shares of Atlassian (TEAM) have gained 0.3% over the past four weeks to close the last trading session at $156.54, but there could still be a solid upside left in the stock if short-term price

Benitec Biopharma Limited (BNTC) closed the last trading session at $13.18, gaining 9.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets

Profound Medical (PROF) closed the last trading session at $6.75, gaining 15.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

From a technical perspective, ATN International, Inc. (ATNI) is looking like an interesting pick, as it just reached a key level of support. ATNI's 50-day simple moving average crossed above its

Shares of Theravance Biopharma (TBPH) have gained 25.8% over the past four weeks to close the last trading session at $18.7, but there could still be a solid upside left in the stock if short-term

Shares of Pagaya Technologies Ltd. (PGY) have gained 6.4% over the past four weeks to close the last trading session at $24.88, but there could still be a solid upside left in the stock if

Shares of Mineralys Therapeutics, Inc. (MLYS) have gained 5.1% over the past four weeks to close the last trading session at $38.91, but there could still be a solid upside left in the stock if

After reaching an important support level, SiBone (SIBN) could be a good stock pick from a technical perspective. SIBN recently experienced a "golden cross" event, which saw its 50-day simple moving

Archer Aviation Inc. (ACHR) closed the last trading session at $8.95, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

Transportadora De Gas Sa Ord B (TGS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TGS's 50-day simple moving average

Sprinklr (CXM) closed the last trading session at $7.9, gaining 5.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy.The strategy helps investors gain

The Campbell's Company CPB is likely to register a decrease in the top and bottom lines when it reports first-quarter fiscal 2026 earnings on Dec. 9. The Zacks Consensus Estimate for revenues is

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates